Surrogate Endpoint, Safety Questions May Be Too Much For Waylivra To Overcome At US FDA Panel
Executive Summary
Akcea Therapeutics' familial chylomicronemia syndrome drug will be faced with questions about its surrogate endpoint and a thrombocytopenia safety signal.
You may also be interested in...
US FDA Limits GMP Exemption For ‘N of 1’ Investigational New Drugs
Agency drafts guidance on how to apply requirements for chemistry, manufacturing and controls, and for good manufacturing practices, to bespoke antisense nucleotides.
2018 Complete Response Letters: Efficacy Issues Drove Most Product Rejections
US FDA issued at least seven rejections to novel products; opioid analgesic sponsors had very little success, while biosimilar developers had a so-so year.
Complete Response Letters See Uptick With US FDA's Thumbs Down For Waylivra
In first half of 2018, CRLs were rarely issued for CDER-regulated novel agents, but FDA's rejection of Waylivra marks second in two weeks.